Core Scientific (CORZ) is back in focus after outlining an expansion plan for its Muskogee, Oklahoma campus that includes acquiring Polaris DS LLC and significantly increasing available power for AI focused data center customers.

The recent expansion announcement comes after a strong run in the stock, with a 90 day share price return of 39.71% and a 1 year total shareholder return of 123.94%. This suggests momentum has been building as Core Scientific pivots further into AI infrastructure and brings experienced data center leadership onto its board.

If this AI focused move has your attention, it could be worth scanning other potential beneficiaries across the sector using our curated list of 47 AI infrastructure stocks

With the stock up sharply over the past year and analysts lifting price targets above the recent US$25.26 close, the key question is whether Core Scientific is still trading at a discount or if the market is already pricing in future growth.

Most Popular Narrative: 4.3% Undervalued

Analysts following Core Scientific see fair value at about $26.40, slightly above the last close at $25.26, and link that gap to aggressive AI hosting expansion and improving profitability assumptions.

The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones. This is expected to drive future revenue growth as data center needs rise. Core Scientific’s ability to diversify its customer base and reduce reliance on CoreWeave as a primary client could improve margins and provide more stable revenue streams in the long term.

Want to see what is built into that fair value gap? The narrative leans on rapid revenue growth, a sharp margin swing, and a future earnings multiple usually reserved for market leaders. Curious which specific earnings and revenue paths underwrite that target and how much optimism is already baked in? The full breakdown lays out every assumption step by step.

Result: Fair Value of $26.40 (UNDERVALUED)

However, there is still real execution risk, ranging from reliance on CoreWeave for a large revenue stream to the company’s recent net loss and post restructuring uncertainty.

Another Angle on Valuation

The analyst narrative points to a fair value of $26.40, only slightly above the recent $25.26 price, and labels Core Scientific undervalued by about 4.3%. Yet the stock trades on a P/S of 22.6x versus 4.7x for peers and a fair ratio of 6.1x, which implies a rich valuation that leaves less room for error if expectations change.

That disconnect between the story and the current P/S level raises a simple question for you as an investor: is this upside case already largely reflected in the price, or do you think the market could still shift closer to the fair ratio over time?

Next Steps

Given this mixed sentiment, do you feel the risk reward trade off still stacks up for you personally? Take a closer look at the full balance of potential upsides and concerns with 1 key reward and 1 important warning sign

Looking for more investment ideas?

If Core Scientific has you thinking bigger about your portfolio, do not stop here. Use focused stock lists to pinpoint ideas that better suit your goals.

• Target potential mispricings by scanning our 48 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Strengthen your income stream by reviewing 10 dividend fortresses that emphasize higher yields paired with resilient profiles.
• Dial down portfolio stress by assessing 65 resilient stocks with low risk scores built around companies with lower risk scores and steadier characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.